Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Prostatic Neoplasms 56Lung Neoplasms 48Leukemia, Myeloid, Acute 44Breast Neoplasms 37Carcinoma, Non-Small-Cell Lung 36Myelodysplastic Syndromes 27Pancreatic Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 24Multiple Myeloma 23Colorectal Neoplasms 23Carcinoma, Renal Cell 22Neoplasm Metastasis 20Melanoma 20Glioblastoma 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Ovarian Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Brain Neoplasms 16Triple Negative Breast Neoplasms 14Squamous Cell Carcinoma of Head and Neck 12Carcinoma, Hepatocellular 12Lymphoma, Mantle-Cell 11Lymphoma, B-Cell 11Leukemia, Myelomonocytic, Chronic 11Fallopian Tube Neoplasms 11Rectal Neoplasms 10Myeloproliferative Disorders 10Lymphoma, Follicular 10Colonic Neoplasms 10Hematopoietic and Lymphatic System Neoplasm 9

Interventions

Interviews as Topic 3Educational Status 3Specimen Handling 2Palliative Care 2Methods 2Early Intervention, Educational 2spartalizumab 1siltuximab 1pembrolizumab 1pamiparib 1cabozantinib 1Pharmacogenomic Variants 1Patient Comfort 1Paclitaxel 1PT-100 dipeptide 1Nutrition Assessment 1Mindfulness-Based Stress Reduction 1Mindfulness 1Magnetic Resonance Spectroscopy 1Health Promotion 1Diet Therapy 1Biopsy 1Behavior Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Advanced Malignant Solid Neoplasm × Specimen Handling × Clear all
NCT06438588 2026-05-22

Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial

Mayo Clinic

Phase NA Recruiting
10 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT06470971 2026-01-20

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
40 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡